Table 3 of
Shpak, Mol Vis 2017; 23:799-809. Table 3 of
Shpak, Mol Vis 2017; 23:799-809.
Table 3. Age and gender characteristics, IOP, medical, laser, and surgical treatment in the main group depending on the POAG stage.
| Variable | POAG stage | P | ||
|---|---|---|---|---|
| 1/2. Early to moderate (n=21) | 3. Advanced (n=18) | 4. Severe (n=16) | ||
| Age | ||||
| mean±SD | 73.3±6.0 | 74.2±5.9 | 69.1±5.9 | 0.031 a |
| range | 55–83 | 60–84 | 58–79 | |
| median (IQR) | 73.0 (71–78) | 75.5 (71–78) | 70.5 (64.8–74) | |
| Sex | ||||
| Women, n (%) | 15 (71%) | 11 (61%) | 6 (37.5%) | |
| IOP, mmHg | ||||
| mean±SD | 17.6±3.7 | 18.4±4.1 | 15.2±4.2 | |
| range | 8–25 | 7–25 | 10–23 | |
| median (IQR) | 17 (16–19) | 19 (17–20.5) | 14 (11–19) | |
| Medications, n (%) | ||||
| β-blockers | 15 (71%) | 15 (83%) | 10 (63%) | |
| Prostaglandin analogs | 7 (33%) | 6 (33%) | 10 (63%) | |
| Topical carbonic anhydrase inhibitors | 8 (38%) | 5 (28%) | 2 (13%) | |
| α2-adrenergic agonists | - | 4 (22%) | 1 (6%) | 0.044 b |
| Laser treatment and surgery | ||||
| SLT | 3 (14%) | 1 (6%) | 1 (6%) | |
| NPDS | 7 (33%) | 7 (39%) | 6 (38%) | |
| NPDS+deferr ed Nd:YAG goniopuncture | 3 (14%) | 5 (28%) | 4 (25%) | |